CL2013000263A1 - Compuestos derivados de carboxamidas azaheterociclicas biciclicas (quinazolinas), como inhibidores de quinasa p70s6k; proceso de preparacion; composicion farmaceutica; kit; y su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer, inflamacion, enfermedades relacionadas con vasculogenesis. - Google Patents
Compuestos derivados de carboxamidas azaheterociclicas biciclicas (quinazolinas), como inhibidores de quinasa p70s6k; proceso de preparacion; composicion farmaceutica; kit; y su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer, inflamacion, enfermedades relacionadas con vasculogenesis.Info
- Publication number
- CL2013000263A1 CL2013000263A1 CL2013000263A CL2013000263A CL2013000263A1 CL 2013000263 A1 CL2013000263 A1 CL 2013000263A1 CL 2013000263 A CL2013000263 A CL 2013000263A CL 2013000263 A CL2013000263 A CL 2013000263A CL 2013000263 A1 CL2013000263 A1 CL 2013000263A1
- Authority
- CL
- Chile
- Prior art keywords
- quinazolines
- vasculogenesis
- inflammation
- cancer
- kit
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003463 hyperproliferative effect Effects 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 230000004862 vasculogenesis Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36896410P | 2010-07-29 | 2010-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000263A1 true CL2013000263A1 (es) | 2013-09-06 |
Family
ID=44532723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000263A CL2013000263A1 (es) | 2010-07-29 | 2013-01-28 | Compuestos derivados de carboxamidas azaheterociclicas biciclicas (quinazolinas), como inhibidores de quinasa p70s6k; proceso de preparacion; composicion farmaceutica; kit; y su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer, inflamacion, enfermedades relacionadas con vasculogenesis. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8710044B2 (es) |
| EP (1) | EP2598492B1 (es) |
| JP (1) | JP5894157B2 (es) |
| KR (1) | KR101852644B1 (es) |
| CN (1) | CN103003250B (es) |
| AR (1) | AR082414A1 (es) |
| AU (1) | AU2011285247B2 (es) |
| BR (1) | BR112013002090A2 (es) |
| CA (1) | CA2806610C (es) |
| CL (1) | CL2013000263A1 (es) |
| EA (1) | EA023132B1 (es) |
| ES (1) | ES2557383T3 (es) |
| IL (1) | IL224072A (es) |
| MX (1) | MX2013001054A (es) |
| NZ (1) | NZ604379A (es) |
| SG (1) | SG187166A1 (es) |
| UA (1) | UA110113C2 (es) |
| WO (1) | WO2012013282A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| BR112013002212A2 (pt) * | 2010-07-29 | 2017-09-26 | Merck Patent Gmbh | carboxamidas aza-heterocíclicas de aminas cíclicas |
| WO2012069146A1 (en) * | 2010-11-24 | 2012-05-31 | Merck Patent Gmbh | Quinazoline carboxamide azetidines |
| SI2755965T1 (sl) | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Novi imidazolni amidi kot modulatorji kinazne aktivnosti |
| SG2014009260A (en) | 2011-09-12 | 2014-09-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| ES2807539T3 (es) | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| JP6386467B2 (ja) | 2012-11-16 | 2018-09-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとしての新規複素環式誘導体 |
| WO2014085528A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
| SG11201505999VA (en) | 2013-03-11 | 2015-08-28 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
| CN103232401B (zh) * | 2013-04-12 | 2015-11-04 | 浙江工业大学 | 一种4-芳硫基喹唑啉类化合物的合成方法 |
| CN103254141B (zh) * | 2013-04-26 | 2016-02-24 | 浙江工业大学 | 4-[4-(2-二丙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用 |
| AU2015240094B2 (en) | 2014-04-03 | 2020-07-30 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| JP6543268B2 (ja) | 2014-04-15 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物 |
| WO2021216548A1 (en) * | 2020-04-21 | 2021-10-28 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| JP2023551408A (ja) | 2020-11-16 | 2023-12-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | がん処置のためのキナーゼインヒビター組み合わせ |
| WO2023039068A1 (en) * | 2021-09-08 | 2023-03-16 | Neubase Therapeutics, Inc. | Compositions and methods for synthesis of peptide nucleic acid intermediates |
| WO2026075985A1 (en) * | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Quinoline- and quinazoline-carboxamide derivatives as cd38 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| JPWO2004014873A1 (ja) * | 2002-08-09 | 2005-12-02 | 杏林製薬株式会社 | ４−置換キナゾリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| AU2003252315A1 (en) * | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| CN100412066C (zh) | 2003-09-30 | 2008-08-20 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| JP2007511575A (ja) | 2003-11-21 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体 |
| TR200808208T1 (tr) | 2003-12-09 | 2008-12-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bir immün tepkinin bastırılması veya proliferatif bir hastalığın tedavisi |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| CA2569404A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| BRPI1008325A2 (pt) * | 2009-02-11 | 2020-08-25 | Merck Patent Gmbh | carboxamidas azaeterocíclicas de amino |
-
2011
- 2011-01-07 UA UAA201302432A patent/UA110113C2/uk unknown
- 2011-07-01 CA CA2806610A patent/CA2806610C/en active Active
- 2011-07-01 EP EP11738160.8A patent/EP2598492B1/en active Active
- 2011-07-01 WO PCT/EP2011/003272 patent/WO2012013282A1/en not_active Ceased
- 2011-07-01 ES ES11738160.8T patent/ES2557383T3/es active Active
- 2011-07-01 BR BR112013002090A patent/BR112013002090A2/pt active Search and Examination
- 2011-07-01 SG SG2013004965A patent/SG187166A1/en unknown
- 2011-07-01 NZ NZ604379A patent/NZ604379A/en not_active IP Right Cessation
- 2011-07-01 KR KR1020137005466A patent/KR101852644B1/ko not_active Expired - Fee Related
- 2011-07-01 JP JP2013520993A patent/JP5894157B2/ja not_active Expired - Fee Related
- 2011-07-01 AU AU2011285247A patent/AU2011285247B2/en not_active Ceased
- 2011-07-01 CN CN201180037284.6A patent/CN103003250B/zh not_active Expired - Fee Related
- 2011-07-01 EA EA201300186A patent/EA023132B1/ru not_active IP Right Cessation
- 2011-07-01 MX MX2013001054A patent/MX2013001054A/es active IP Right Grant
- 2011-07-01 US US13/703,276 patent/US8710044B2/en active Active
- 2011-07-29 AR ARP110102741A patent/AR082414A1/es active IP Right Grant
-
2012
- 2012-12-31 IL IL224072A patent/IL224072A/en active IP Right Grant
-
2013
- 2013-01-28 CL CL2013000263A patent/CL2013000263A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL224072A0 (en) | 2013-03-05 |
| AR082414A1 (es) | 2012-12-05 |
| US8710044B2 (en) | 2014-04-29 |
| AU2011285247A1 (en) | 2013-03-14 |
| CN103003250B (zh) | 2016-02-17 |
| JP2013532668A (ja) | 2013-08-19 |
| EP2598492B1 (en) | 2015-10-28 |
| EA023132B1 (ru) | 2016-04-29 |
| AU2011285247B2 (en) | 2016-08-04 |
| WO2012013282A8 (en) | 2012-03-29 |
| WO2012013282A1 (en) | 2012-02-02 |
| CA2806610A1 (en) | 2012-02-02 |
| KR101852644B1 (ko) | 2018-04-26 |
| ES2557383T3 (es) | 2016-01-25 |
| CA2806610C (en) | 2018-08-28 |
| EP2598492A1 (en) | 2013-06-05 |
| KR20130096714A (ko) | 2013-08-30 |
| EA201300186A1 (ru) | 2013-12-30 |
| NZ604379A (en) | 2015-01-30 |
| US20130137677A1 (en) | 2013-05-30 |
| BR112013002090A2 (pt) | 2016-05-24 |
| JP5894157B2 (ja) | 2016-03-23 |
| MX2013001054A (es) | 2013-02-21 |
| CN103003250A (zh) | 2013-03-27 |
| SG187166A1 (en) | 2013-02-28 |
| UA110113C2 (xx) | 2015-11-25 |
| IL224072A (en) | 2016-02-29 |
| HK1183302A1 (zh) | 2013-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023222B8 (ru) | Пиразолилхиноксалиновые ингибиторы киназы | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| WO2012013282A8 (en) | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| CL2014001090A1 (es) | Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| JO3419B1 (ar) | مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr | |
| MX349004B (es) | Nuevos compuestos. | |
| IL236221A (en) | History of theophyridone and pharmacological preparations containing them for the treatment of diseases | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| BR112013003671A2 (pt) | composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| PL3443957T3 (pl) | Związki i kompozycje stosowane w leczeniu nowotworów | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| DK2655532T3 (da) | Afvisende coatingsammensætning og coating, fremgangsmåde til fremstilling og anvendelse heraf | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| CL2013002971A1 (es) | Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas. | |
| SMT201500066B (it) | Composto di indazolo triciclico, metodo di preparazione e composizione farmaceutica che lo contiene | |
| CL2014001323A1 (es) | Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| ZA201306905B (en) | Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these |